Given the aforementioned studies demonstrating that PHLPP plays an important role in tumor progression and treatment resistance, it seems reasonable to speculate that TKI could not fully inhibit PHLPP loss-mediated AKT S473 phosphorylated to cause TKI resistance in PHLPP downregulation EGFR-mutant lung cancer cells. This evidence concerns the gene EGFR and lung carcinoma.